Integrated Automated Insulin Delivery System and Long-Term Glucose Monitoring System Developed by Sequel Med Tech and Senseonics
In a groundbreaking development for people living with diabetes, the integrated twiist Automated Insulin Delivery (AID) system paired with Senseonics' Eversense 365 implantable Continuous Glucose Monitoring (CGM) system is set to become available in the United States within the next few months.
The phased rollout of the twiist AID system began in July 2025, initially with Abbott's FreeStyle Libre 3 Plus CGM. Compatibility with Senseonics' Eversense 365 CGM is planned for release within months after the initial launch, expected by the fourth quarter of 2025. Full U.S. national availability of twiist with both CGM options is targeted by the end of 2025.
This strategic approach ensures clinical readiness, user support, and provider preparation for people with type 1 diabetes seeking an automated insulin delivery solution with a long-term implantable CGM.
Senseonics, a company pioneering long-duration CGM technology, has experienced strong growth in the adoption of the Eversense 365 CGM. In Q2 2025, there was a 79% year-over-year increase in new U.S. patient starts, and expanded Medicare reimbursement supports broader access. This momentum is expected to support the uptake of the integrated AID system when the twiist-Eversense compatibility becomes available.
The twiist AID system, developed by Sequel Med Tech, is an all-in-one patch pump that offers greater personalization, more choice, and the potential for improved outcomes for people living with diabetes. The integrated system will be the first AID system compatible with the Senseonics Eversense 365, a one-year CGM system.
Sequel Med Tech remains committed to advancing diabetes technology and expanding partnerships to give people with diabetes more choice and flexibility in managing their diabetes. This collaboration between Sequel and Senseonics marks a significant step forward in transforming diabetes care.
In related news, the Simplera Sync sensor for MiniMed 780G has received FDA approval, further highlighting the ongoing efforts to improve diabetes management. Supporting a new wave of young diabetics is also crucial, as stated in a related article in "Medical Plastics Insights".
PharmaSens and SiBionics have also collaborated to advance an all-in-one patch pump, signifying a continued push towards innovative solutions for diabetes management. The integrated twiist AID system and Eversense 365 CGM are poised to make a substantial impact on diabetes care in the near future.
- The integrated twiist Automated Insulin Delivery (AID) system, developed by Sequel Med Tech, is expected to have a significant impact on diabetes care, as it will be the first AID system compatible with the Senseonics Eversense 365, a one-year CGM system, making it a potential solution for people managing chronic diseases like type-2 diabetes and various medical-conditions.
- Senseonics, a company focused on long-duration Continuous Glucose Monitoring (CGM) technology, has experienced growth in the adoption of the Eversense 365 CGM, which could support the uptake of the integrated twiist AID system when the twiist-Eversense compatibility is released, contributing to the broader health-and-wellness and health management landscape.
- As diabetes care continues to evolve, companies like Sequel Med Tech and Senseonics are advancing technology and expanding partnerships to offer more options for personalized nutrition and care to help people with diabetes manage their conditions effectively, in line with the goals of the science and medical community.
